Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

15.6K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
15.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

14.3K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
14.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing the spleen-brain axis: Magnolol-loaded nanomedicine attenuates ischemic stroke <i>via</i> oxidative stress mitigation and monocyte/macrophage reprogramming.

Acta pharmaceutica Sinica. B·2026
Same author

The structural basis of RanGAP1 regulation and catalysis in nuclear transport.

bioRxiv : the preprint server for biology·2026
Same author

Antioxidant Nanozymes: From Rational Design to Biomedical Applications.

Research (Washington, D.C.)·2026
Same author

The feasibility of ovarian tissue cryopreservation in selected females after hematopoietic stem cell transplantation.

Bone marrow transplantation·2026
Same author

Nanoporous-based biomaterials in biomedical applications: from fundamentals and biosensing to drug delivery, wound healing, and tissue engineering.

Nanoscale advances·2026
Same author

Long-term assessment of nutrient-induced eutrophication in Xiamen Bay: Implications for integrated watershed-coast management.

Marine environmental research·2026

Related Experiment Video

Updated: Nov 26, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K

Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.

Ruth Nussinov1,2, Mingzhen Zhang3, Chung-Jung Tsai3

  • 1Computational Structural Biology Section, Frederick National Laboratory for Cancer Research in the Laboratory of Cancer Immunometabolism, NCI, Frederick, Maryland. NussinoR@mail.nih.gov.

Molecular Cancer Research : MCR
|December 8, 2020
PubMed
Summary

Phosphatidylinositol 3-kinases (PI3K) and PTEN proteins are frequently mutated in cancer. Structural insights reveal how mutations and phosphorylation control their autoinhibited states, impacting cell growth and offering new therapeutic targets.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.3K

Related Experiment Videos

Last Updated: Nov 26, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.3K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.3K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • PI3K and PTEN are critical regulators of cell signaling, opposing each other's actions on the PIP2/PIP3 lipid.
  • Mutations in PI3K and PTEN are highly prevalent in cancer, leading to uncontrolled cell-cycle progression.
  • Autoinhibition is a key regulatory mechanism for PI3K and PTEN, involving structural occlusion of their active sites.

Purpose of the Study:

  • To review structural aspects of autoinhibition in PI3K and PTEN.
  • To clarify how phosphorylation and mutations influence these autoinhibited states.
  • To explore the implications for allosteric precision oncology.

Main Methods:

  • Structural analysis of PI3K and PTEN.
  • Review of phosphorylation events and mutations affecting autoinhibition.
  • Mechanistic interpretation of protein-protein interfaces and their stability.

Main Results:

  • Autoinhibition in PI3K and PTEN involves occlusion of the functional site by specific protein segments or subunits.
  • Phosphorylation can stabilize or destabilize these autoinhibiting interfaces.
  • Driver mutations commonly destabilize interfaces, leading to protein activation and promoting cancer.
  • The concept of 'passenger phosphorylation' is introduced to distinguish functional from statistical phosphorylation events.

Conclusions:

  • Structural understanding of PI3K and PTEN autoinhibition is crucial for comprehending oncogenic activation.
  • Destabilization of autoinhibitory interfaces by mutations is a key driver of cancer.
  • Targeting these mechanisms offers potential for developing novel allosteric cancer therapies.